Skip to content
10-Q

Quarterly Report

Ocular Therapeutix, Inc. OCUL

0001104659-26-055256

← back to feed
Filed
May 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 218.96M sh
Shares Diluted Q1 2026 · Mar 31, 2026 224.1M sh
Shares Diluted Q1 2026 · Mar 31, 2025 169.4M sh
Capex Q1 2026 · Mar 31, 2026 $4.66M
Capex Q1 2026 · Mar 31, 2025 $1.93M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$65.99M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$44.67M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $666.7M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $737.06M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $349.68M
Stockholders Equity Q1 2026 · Mar 31, 2026 $581.57M
Stockholders Equity Q1 2026 · Dec 31, 2025 $654.31M
Stockholders Equity Q1 2026 · Mar 31, 2025 $265.93M
Stockholders Equity Q1 2026 · Dec 31, 2024 $315.34M
Current Liabilities Q1 2026 · Mar 31, 2026 $47.68M
Current Liabilities Q1 2026 · Dec 31, 2025 $50.81M
Total Liabilities Q1 2026 · Mar 31, 2026 $150.96M
Total Liabilities Q1 2026 · Dec 31, 2025 $153.75M
Current Assets Q1 2026 · Mar 31, 2026 $706M
Current Assets Q1 2026 · Dec 31, 2025 $782.13M
Total Assets Q1 2026 · Mar 31, 2026 $732.53M
Total Assets Q1 2026 · Dec 31, 2025 $808.06M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.40
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.38
Eps Basic Q1 2026 · Mar 31, 2026 −$0.40
Eps Basic Q1 2026 · Mar 31, 2025 −$0.38
Sga Expense Q1 2026 · Mar 31, 2026 $20.01M
Sga Expense Q1 2026 · Mar 31, 2025 $16.35M
Rd Expense Q1 2026 · Mar 31, 2026 $66.21M
Rd Expense Q1 2026 · Mar 31, 2025 $42.86M
Net Income Q1 2026 · Mar 31, 2026 −$88.61M
Net Income Q1 2026 · Mar 31, 2025 −$64.05M
Operating Income Q1 2026 · Mar 31, 2026 −$93.34M
Operating Income Q1 2026 · Mar 31, 2025 −$63.92M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $1.33M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $1.26M
Revenue Q1 2026 · Mar 31, 2026 $10.79M
Revenue Q1 2026 · Mar 31, 2025 $10.7M